AUTL
Price
$2.12
Change
-$0.03 (-1.40%)
Updated
Jun 13 closing price
Capitalization
564.21M
46 days until earnings call
CGEN
Price
$1.64
Change
-$0.02 (-1.20%)
Updated
Jun 13 closing price
Capitalization
144.24M
46 days until earnings call
Interact to see
Advertisement

AUTL vs CGEN

Header iconAUTL vs CGEN Comparison
Open Charts AUTL vs CGENBanner chart's image
Autolus Therapeutics
Price$2.12
Change-$0.03 (-1.40%)
Volume$1.9M
Capitalization564.21M
Compugen
Price$1.64
Change-$0.02 (-1.20%)
Volume$173.68K
Capitalization144.24M
AUTL vs CGEN Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. CGEN commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a StrongBuy and CGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (AUTL: $2.12 vs. CGEN: $1.64)
Brand notoriety: AUTL and CGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 77% vs. CGEN: 70%
Market capitalization -- AUTL: $564.21M vs. CGEN: $144.24M
AUTL [@Biotechnology] is valued at $564.21M. CGEN’s [@Biotechnology] market capitalization is $144.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $356.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileCGEN’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • CGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, both AUTL and CGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 6 TA indicator(s) are bullish while CGEN’s TA Score has 6 bullish TA indicator(s).

  • AUTL’s TA Score: 6 bullish, 4 bearish.
  • CGEN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both AUTL and CGEN are a good buy in the short-term.

Price Growth

AUTL (@Biotechnology) experienced а -9.40% price change this week, while CGEN (@Biotechnology) price change was -5.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

AUTL is expected to report earnings on Jul 31, 2025.

CGEN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($564M) has a higher market cap than CGEN($144M). CGEN YTD gains are higher at: 7.190 vs. AUTL (-9.787). CGEN has higher annual earnings (EBITDA): -14.79M vs. AUTL (-226.02M). AUTL has more cash in the bank: 517M vs. CGEN (104M). CGEN has less debt than AUTL: CGEN (2.77M) vs AUTL (57.7M). CGEN has higher revenues than AUTL: CGEN (27.6M) vs AUTL (9.01M).
AUTLCGENAUTL / CGEN
Capitalization564M144M392%
EBITDA-226.02M-14.79M1,528%
Gain YTD-9.7877.190-136%
P/E RatioN/A60.33-
Revenue9.01M27.6M33%
Total Cash517M104M497%
Total Debt57.7M2.77M2,082%
FUNDAMENTALS RATINGS
AUTL vs CGEN: Fundamental Ratings
AUTL
CGEN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
3947
P/E GROWTH RATING
1..100
10027
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for CGEN (76). This means that AUTL’s stock grew somewhat faster than CGEN’s over the last 12 months.

AUTL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CGEN (100). This means that AUTL’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (95) in the Biotechnology industry is in the same range as AUTL (97). This means that CGEN’s stock grew similarly to AUTL’s over the last 12 months.

AUTL's Price Growth Rating (39) in the Biotechnology industry is in the same range as CGEN (47). This means that AUTL’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for AUTL (100). This means that CGEN’s stock grew significantly faster than AUTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLCGEN
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 19 days ago
82%
Bullish Trend about 1 month ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGIQX15.65-0.15
-0.95%
Macquarie Growth and Income R6
MSHPX14.68-0.16
-1.08%
Morgan Stanley Inst Permanence R6
GPAFX57.89-0.72
-1.23%
Victory RS Large Cap Alpha A
CSXCX46.39-0.63
-1.34%
Calvert US Large Cap Core Rspnb Idx C
VYSZX5.47-0.12
-2.15%
Voya Small Company C

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
-1.40%
CRSP - AUTL
50%
Loosely correlated
+0.19%
OCUL - AUTL
48%
Loosely correlated
-2.46%
IDYA - AUTL
46%
Loosely correlated
-0.45%
ATAI - AUTL
45%
Loosely correlated
-3.21%
SCPH - AUTL
44%
Loosely correlated
-1.25%
More

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with BDTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-1.20%
BDTX - CGEN
44%
Loosely correlated
-4.94%
ROIV - CGEN
41%
Loosely correlated
-1.31%
RLAY - CGEN
39%
Loosely correlated
-6.67%
ITOS - CGEN
39%
Loosely correlated
+1.90%
AUTL - CGEN
39%
Loosely correlated
-1.40%
More